{"id":3963,"date":"2019-01-17T12:09:12","date_gmt":"2019-01-17T06:39:12","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3963"},"modified":"2023-01-05T10:06:04","modified_gmt":"2023-01-05T04:36:04","slug":"the-business-cocktail-52","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-52","title":{"rendered":"Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raises"},"content":{"rendered":"\n<p><strong>Anti-aging\nstartup Juvenescence raises USD 46 Million <\/strong><\/p>\n\n\n\n<p class=\"has-background\" style=\"background-color:#7dd5b5\"><strong>Juvenescence <\/strong>has\u00a0bagged\u00a0the<strong> USD 46 million<\/strong> in <strong>series B financing<\/strong>. The investment tees the anti-<a href=\"https:\/\/www.delveinsight.com\/report-store\/ageing-pipeline-insight\" class=\"ek-link\">ageing <\/a>startup to progress the multi-asset pipeline. <strong>Jim Mellon<\/strong>, a British billionaire biotech investor, created Juvenescence with early <strong>Medivation backer Greg Bailey<\/strong> and three others in 2017. Since then, the founders have utilised their capital and contacts to increase the growth of Juvenescence with <strong>USD 115 million<\/strong> in investment. Juvenescence hopes regarding figure to increase when it closes the next tranche of a forecast USD 100 million round.<\/p>\n\n\n\n<p><strong>Brainsway\nfiles for USD 30 Million Nasdaq IPO<\/strong><\/p>\n\n\n\n<p class=\"has-background\" style=\"background-color:#7dd5b5\"><strong>Brainsway<\/strong><g class=\"gr_ gr_13 gr-alert gr_gramm gr_inline_cards gr_run_anim Style replaceWithoutSep\" id=\"13\" data-gr-id=\"13\">,<\/g><g class=\"gr_ gr_13 gr-alert gr_gramm gr_inline_cards gr_disable_anim_appear Style replaceWithoutSep\" id=\"13\" data-gr-id=\"13\">the<\/g> developer of m<strong>agnetic device treatments f<\/strong>or <a href=\"https:\/\/www.delveinsight.com\/report-store\/treatment-resistant-depression-trd-market-size\">depression <\/a>and obsessive-compulsive disorder, contemplates <g class=\"gr_ gr_6 gr-alert gr_gramm gr_inline_cards gr_run_anim Grammar multiReplace\" id=\"6\" data-gr-id=\"6\">to file<\/g> USD 30 million through an <strong>initial public offering <\/strong>on the <strong>Nasdaq<\/strong>. The <strong>Jerusalem-based <\/strong>company privately filed and the pricing terms were not disclosed. The company obtained a de novo clearance from the <strong>FDA <\/strong>for the use of its noninvasive, <strong>deep transcranial stimulation system <\/strong>in treating<strong> OCD<\/strong> through about 20-minute-long sessions. <\/p>\n\n\n\n<p><strong>Life\nBiosciences raises USD 50 Million <\/strong><\/p>\n\n\n\n<p class=\"has-background\" style=\"background-color:#7dd5b5\"><strong>Life Biosciences<\/strong> has\u00a0raised\u00a0<strong>USD 50 million<\/strong>. The series B round will bolster the efforts of startup for building a portfolio of subsidiaries with assets targeting eight aging pathways. Life Biosciences is channelling capital into a bunch of startups that are working on different ways to attack <a href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-macular-degeneration-amd-market\" class=\"ek-link\">age-related diseases<\/a><strong> <\/strong>for extending healthy life spans. The has led the company to found six subsidiaries that have access to shared lab space and artificial intelligence capabilities as well as to invest in <strong>Prana Biotechnology.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anti-aging startup Juvenescence raises USD 46 Million Juvenescence has\u00a0bagged\u00a0the USD 46 million in series B financing. The investment tees the anti-ageing startup to progress the multi-asset pipeline. Jim Mellon, a British billionaire biotech investor, created Juvenescence with early Medivation backer Greg Bailey and three others in 2017. Since then, the founders have utilised their capital [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3895,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2440,2433,704,2432,1728,2430,2429,2438,2434,2431,2437,2439],"industry":[17225],"therapeutic_areas":[17229,17278],"class_list":["post-3963","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-age-related-diseases","tag-brainsway","tag-fda","tag-greg-bailey","tag-ipo","tag-jim-mellon","tag-juvenescence","tag-life-biosciences","tag-magnetic-device-treatments","tag-medivation","tag-ocd","tag-rana-biotechnology","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raise<\/title>\n<meta name=\"description\" content=\"\ufeffJuvenescence has bagged the USD 46 million in series B financing. The investment tees the anti-ageing startup to progress the....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-52\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raise\" \/>\n<meta property=\"og:description\" content=\"\ufeffJuvenescence has bagged the USD 46 million in series B financing. The investment tees the anti-ageing startup to progress the....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-52\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-17T06:39:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-05T04:36:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raise","description":"\ufeffJuvenescence has bagged the USD 46 million in series B financing. The investment tees the anti-ageing startup to progress the....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-52","og_locale":"en_US","og_type":"article","og_title":"Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raise","og_description":"\ufeffJuvenescence has bagged the USD 46 million in series B financing. The investment tees the anti-ageing startup to progress the....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-52","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-01-17T06:39:12+00:00","article_modified_time":"2023-01-05T04:36:04+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-52","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-52","name":"Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raise","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-52#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-52#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co.jpg","datePublished":"2019-01-17T06:39:12+00:00","dateModified":"2023-01-05T04:36:04+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"\ufeffJuvenescence has bagged the USD 46 million in series B financing. The investment tees the anti-ageing startup to progress the....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-52"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-52#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co.jpg","width":1920,"height":1080,"caption":"Juvenescence"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">age-related diseases<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Brainsway<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Greg Bailey<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IPO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Jim Mellon<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Juvenescence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Life Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">magnetic device treatments<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medivation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">OCD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rana Biotechnology.<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">age-related diseases<\/span>","<span class=\"advgb-post-tax-term\">Brainsway<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Greg Bailey<\/span>","<span class=\"advgb-post-tax-term\">IPO<\/span>","<span class=\"advgb-post-tax-term\">Jim Mellon<\/span>","<span class=\"advgb-post-tax-term\">Juvenescence<\/span>","<span class=\"advgb-post-tax-term\">Life Biosciences<\/span>","<span class=\"advgb-post-tax-term\">magnetic device treatments<\/span>","<span class=\"advgb-post-tax-term\">Medivation<\/span>","<span class=\"advgb-post-tax-term\">OCD<\/span>","<span class=\"advgb-post-tax-term\">rana Biotechnology.<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jan 17, 2019","modified":"Updated on Jan 5, 2023"},"absolute_dates_time":{"created":"Posted on Jan 17, 2019 12:09 pm","modified":"Updated on Jan 5, 2023 10:06 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3963"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3963\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3895"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3963"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3963"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}